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Abstract
Background—Cervical cancer incidence in the US-Affiliated Pacific Islands (USAPIs) is double 
that of the US mainland. American Samoa, Commonwealth of Northern Mariana Islands (CNMI), 
Guam and the Republic of Palau receive funding from the Centers for Disease Control (CDC) 
National Breast and Cervical Cancer Early Detection Program (NBCCEDP) to implement cervical 
cancer screening to low-income, uninsured or under insured women. The USAPI grantees report 
data on screening and follow-up activities to the CDC.
Materials and methods—We examined cervical cancer screening and follow-up data from the 
NBCCEDP programs in the four USAPIs from 2007 to 2015. We summarized screening done by 
Papanicolaou (Pap) and oncogenic human papillomavirus (HPV) tests, follow-up and diagnostic 
tests provided, and histology results observed.
Results—A total of 22,249 Pap tests were conducted in 14,206 women in the four USAPIs 
programs from 2007–2015. The overall percentages of abnormal Pap results (low-grade squamous 
intraepithelial lesions or worse) was 2.4% for first program screens and 1.8% for subsequent 
program screens. Histology results showed a high proportion of cervical intraepithelial neoplasia 
grade 2 or worse (57%) among women with precancers and cancers. Roughly one-third (32%) of 
Pap test results warranting follow-up had no data recorded on diagnostic tests or follow-up done.
Conclusion—This is the first report of cervical cancer screening and outcomes of women served 
in the USAPI through the NBCCEDP with similar results for abnormal Pap tests, but higher 
proportion of precancers and cancers, when compared to national NBCCEDP data. The USAPI 
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face significant challenges in implementing cervical cancer screening, particularly in providing 
and recording data on diagnostic tests and follow-up. The screening programs in the USAPI 
should further examine specific barriers to follow-up of women with abnormal Pap results and 
possible solutions to address them.
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1. Introduction
The US-Affiliated Pacific Islands (USAPI) are comprised of three US flag jurisdictions: 
territories of American Samoa, Guam, and the Commonwealth of the Northern Mariana 
Islands (CNMI), and three Freely Associated States: the Republic of Palau, the Federated 
States of Micronesia (FSM) and the Republic of the Marshall Islands (RMI) (Fig. 1). The 
USAPI are populated by more than 450,000 people living on hundreds of islands and atolls, 
occupying greater than one million ocean square miles, and crossing five Pacific Time zones 
and the International Date Line [1]. Cervical cancer is one of the leading causes of cancer 
death in women in the USAPI and cervical cancer incidence in the USAPIs (20.6 per 
100,000) was more than two-fold that in the US mainland (7.8 per 100,000) between 2007 
and 2011 [2,3]. There is limited population-level data on cervical cancer screening in the 
USAPI jurisdictions, but screening coverage estimates are generally lower than in the US 
mainland. The percentage of women who had a Papanicolaou (Pap) test in the past 5 years 
was reported to be 55% in Palau in 2006, and 53.5% in CNMI in 2015, compared to 88.6% 
in the US mainland in 2012 [3–5].
The Centers for Disease Control (CDC)’s National Breast and Cervical Cancer Early 
Detection Program (NBCCEDP) provides funding to US states, tribes and territories to 
deliver breast and cervical cancer screening to low-income, uninsured or under insured 
women [6]. The NBCCEDP is a collection of individual programs that operate within a 
national program framework of legislation, policy, and oversight. Each state/territory grantee 
establishes an operational model unique to their public health infrastructure that includes 
strategies to reach eligible women in underserved communities and a provider network to 
deliver services. Program implementation decisions are made by states/territories and vary 
among grantees [7]. Four USAPI territories receive NBCCEDP funding: American Samoa 
(1998-present), Guam (2002-present), Palau (1998-present) and CNMI (1998–2002, 2007-
present). The screening programs in the four USAPIs follow screening recommendations 
from the U.S Preventive Services Task Force (USPSTF); women aged 21–65 years are 
screened using a Pap test every 3 years, or every 5 years if an oncogenic human 
papillomavirus (HPV) test is administered with a Pap test (co-testing) for women aged 30–
65 years [8]. These USPSTF recommendations for cervical cancer screening were released 
in March 2012, and CDC asked grantees to implement them by July 2012. Prior to 2012, 
screening programs in the USAPI followed previous USPSTF screening recommendations 
that did not include HPV testing, and allowed for screening of women under the age of 21, 
based on age of onset of sexual activity [9]. The screening programs in the USAPI adhere to 
the American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines for 
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follow-up of women with abnormal Pap results [10]. In addition to the NBCCEDP, 
government support for cervical cancer screening in the USAPI is also provided by the Title 
X Family Planning program, the Maternal Child Health program and the Health Resources 
Services Administration (HRSA) Community Health Center Program (Table 1).
Cervical cancer screening programs in the USAPI face several technical, geographical and 
socioeconomic challenges in providing screening and treatment for precancerous and 
cancerous cervical lesions. None of the USAPIs have a certified laboratory to process Pap or 
HPV screening tests on-island; currently all CDC-funded screening programs in the USAPI 
ship their specimens to laboratories in Los Angeles or Hawaii for testing. Screening 
programs have to pay high shipping costs for the specimens and wait longer to receive 
results (turnaround time of up to one-month) (NBCCEDP program staff in the USAPI, 
personal communication, December 6, 2016). Follow-up of women with abnormal results is 
challenging since there is no public transportation on most islands, and some women live on 
outer islands or atolls with limited ship or air transportation to health centers on the main 
islands for multiple visits [11]. American Samoa, Palau and CNMI have a combined total of 
17 vastly dispersed outer islands with women served by the NBCCEDP. Treatment of 
women with precancerous cervical lesions is limited by lack of medical grade carbon 
dioxide for cryotherapy or the inability to perform loop electrosurgical excision procedures 
(LEEPs) on-island [11].
In spite of all these challenges, the CDC-funded screening programs in the four USAPIs 
have been providing cervical cancer screening to women for the last 15 years. In this 
analysis, we examine the cervical cancer screening and diagnostic services provided, and 
outcomes observed in women served by the NBCCEDP in the four USAPI jurisdictions 
from 2007 to 2015. We limited our analysis to 2007–2015 since all four USAPI jurisdictions 
received NBCCEDP funding continuously during this period.
2. Methods
The CDC collects a standardized set of data variables, referred to as the Minimum Data 
Elements (MDEs), to monitor the implementation and results of the NBCCEDP’s screening, 
diagnostic and follow-up activities (OMB # 0920-0571). The composition and quality of the 
MDEs been previously described in-detail elsewhere [12,13]. For this analysis, we examined 
MDEs from the four funded USAPIs: American Samoa, CNMI, Guam and the Republic of 
Palau, from 2007 to 2015. This study was approved by CDC’s Institutional Review Board.
The MDEs contain information on cervical cancer screening by Pap test and by oncogenic 
human papillomavirus (HPV) testing; women enrolled in the NBCCEDP are assigned a 
unique identification number to track screening and diagnostic services provided to them 
over time. Pap test results for the 2007–2015 period were reported using the Bethesda 2001 
system categories [14]. We present the total number of Pap tests conducted by the four 
USAPIs each calendar year, the range of total Pap tests conducted per island, as well as the 
range of total unduplicated women screened by Pap test per island. We examined Pap test 
results by age, calculated using birth date reported at enrollment, and classified into 6 age 
categories: 18–29, 30–39, 40–49, 50–59, 60–64 and 65 years and older. We examined the 
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percentage of women with abnormal Pap test results, defined as results of low-grade 
squamous intraepithelial lesion (LSIL) or worse. We also examined Pap test results for 
women’s first screen in the NBCCEDP (first round) and for all subsequent screens in the 
time period (subsequent rounds).
Two of the four USAPIs performed HPV testing (triage or co-testing) between 2007 and 
2015; we summarized the total number of HPV tests conducted each year, as well as the 
range of total HPV tests conducted per island each year. In 2012, the USPSTF 
recommendations included the administration of HPV testing along with Pap testing (co-
testing) in women 30–65 years [8]. The NBCCEDP asked states and territories to implement 
the new screening recommendation, including co-testing, by July 2012. HPV test data 
reported prior to the implementation of co-testing in the NBCCEDP in 2012 was from 
testing done to triage abnormal Pap test results. HPV data after July 2012 includes both 
triage and co-testing.
We examined follow-up and diagnostic tests conducted within each cervical cancer 
screening cycle, which was defined as the time between the Pap test date and the date of the 
diagnostic test or 6 months after the end of the screening calendar year. The categories for 
diagnostic procedures were: colposcopy with directed biopsy, colposcopy without biopsy, 
endocervical curettage alone (ECC), loop electrosurgical excision procedure (LEEP), cold 
knife conization and other procedures. The ‘Other’ category indicates gynecologic visits 
made by women, but records did not specify the type of diagnostic tests or procedures done 
during the visit. We examined the number of follow-up and diagnostic test procedures by 
Pap and HPV testing done.
We also examined the percentage of biopsy-confirmed precancers or cancers for women 
screened in the program by self-reported age and race, first versus subsequent screening, and 
screening year. Histology results were categorized as low-grade CIN (cervical intraepithelial 
neoplasia (CIN) grade 1), high-grade CIN (CIN2 or CIN3) and invasive cervical cancer 
(ICC). We examined the rates of the biopsy-confirmed precancers or cancers per 1000 Pap 
tests based on the women’s most severe outcomes during the study period. Due to the 
relatively small numbers in the low-grade CIN, high-grade CIN and ICC categories, we did 
not perform any statistical tests to compare rates across categories of any of the descriptive 
variables.
3. Results
A combined total of 22, 249 Pap tests were conducted in 14,206 women by the four USAPI 
grantees between 2007 and 2015. The total number of Pap tests conducted was highest in 
2008 (total = 4043 Pap tests), and notably decreased yearly from 2009 through 2012. (Fig. 
2a). Two of the four USAPIs performed HPV testing for triage or co-testing between 2007 
and 2015 and overall, very few HPV tests (total = 1203 HPV tests) were performed by these 
two islands, in comparison to Pap tests conducted during this period (Fig. 2b). An increase 
in HPV tests conducted was observed for 2009 when NBCCEDP required states to start 
reporting HPV test data comprehensively. The total number of HPV tests conducted every 
year increased annually between 2012 and 2015.
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Pap test results for the first program screen and subsequent program screens are shown in 
(Table 2). The overall percentage of abnormal Pap test results in the first round was 2.4%, 
and appeared to decrease in subsequent screening rounds to 1.8%. In both first and 
subsequent round screenings, the percentage of abnormal Pap results generally decreased 
with increasing age, with the highest percentage in women aged 18–29 years, and the lower 
percentages in women aged 50–59, 60–64 and 65 years or older. The decrease in the 
percentage of abnormal Pap tests in subsequent screening rounds was seen for older women, 
but little or no difference was seen for women 59 years and younger. The overall percentage 
of results found to be atypical squamous cells of unknown significance (ASC-US) or 
unsatisfactory appeared to increase in subsequent screens compared to the first screening 
round.
Screening records with “Unsatisfactory” or “Other” Pap test results were excluded from 
follow-up analyses; a total of 21, 872 (98.3%) cervical cancer screens had valid Pap test 
results and were included in analyses on follow-up and diagnostic procedures done (Table 
3). A total of 515 screens had Pap or oncogenic HPV test results warranting follow-up or 
diagnostic procedures; 456 (2.1%) screens had abnormal low- or high-grade Pap results and 
59 (0.3%) had ASC-US and HPV-positive results. Of these 515 Pap screens, colposcopy 
with directed-biopsy was performed for 243 (47.2%) screens, colposcopy with no biopsy 
was performed for 12 (2.3%) screens, ECC alone was performed for 7 (1.4%) screens, other 
or unspecified tests were done for 87 (16.9%) screens, and 166 (32.2%) screens had no data 
on diagnostic tests or follow-up done. A small number of Pap screens with normal results 
reported having diagnostic tests or follow-up done (0.2%, n = 37 screens), including 
colposcopy with directed biopsy (0.07%, n = 16 screens).
Histological outcomes of women screened are described in Table 4. There were 68 low-
grade CIN, 80 high-grade CIN and 10 ICC cases detected in the 14,206 unique women 
screened in the period examined. The majority of low-grade CIN were detected in women 
younger than 50 years, with the greatest percentage detected in women aged 18–29 years 
(35.3%). The rates of low-grade CIN (per 1000 Pap tests) were higher in younger women 
aged 18–29 years, compared to other age groups. The majority of high-grade CIN were also 
detected in women aged 49 years or younger, with the greatest percentage detected in 
women aged 40–49 years (36.3%). The rates of high-grade CIN (per 1000 Pap tests) 
appeared to be higher in women aged 49 years or younger, compared to older women. There 
were no ICC cases in women aged 18–29 years and the majority of ICC cases were in 
women aged 40–49 years (40%). The ICC rates (per 1000 Pap tests) appeared to be higher in 
older women, aged 60 years and older, compared to younger women. The majority of low-
grade CIN (60%), high-grade CIN (56%) and ICC (60%) were detected in the first round 
screens, compared to subsequent screens, and the rates per 1000 Pap tests appeared to be 
higher in first versus subsequent rounds. The rates of precancers or cancers detected varied 
each year; no apparent trend was seen in these rates between 2007 and 2015.
4. Discussion
This is the first report of cervical cancer screening and outcomes of women served by the 
NBCCEDP in the four US-Affiliated Pacific Islands. The 14,206 women screened for 
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cervical cancer from 2007 to 2015 represent roughly 17.9% of all women aged 20–64 years 
in the four USAPI jurisdictions (Table 1); the total number of women who qualify for 
NBCCEDP in the four USAPIs based on limited or no-insurance and low-income 
requirements is unknown. The reach of the NBCCEDP in providing cervical cancer 
screening to women in the USAPI is partly limited by the unique technical and geographical 
challenges faced in this region. During the 2007–2015 period, some of the USAPI 
jurisdictions could not reach eligible women in their outer islands for cervical screening due 
to the lack of ship or airline transportation to these outer islands in some years (NBCCEDP 
program staff in the USAPI, personal communication, December 6, 2016). This challenge in 
reaching some of the USAPI outer islands may explain some of the annual variation seen in 
the total number of Pap and HPV tests provided by the NBCCEDP during this period.
Only two of the four USAPI grantees conducted any HPV testing (for triage or co-testing), 
and overall, very few HPV tests were conducted in this period. The USAPIs have to ship 
specimens to Hawaii or Los Angeles for Pap or HPV testing since none of the four 
jurisdictions currently have the capacity to process these tests on-island (NBCCEDP 
program staff in the USAPI, personal communication, December 6, 2016) [15]. The 
implementation of HPV testing in the USAPI has been slow, partly due to challenges that 
USAPI face in planning for high shipping and testing costs and also coordinating with the 
off-island laboratories to ensure timely processing and receipt of screening results.
The distribution of Pap test results by screening round in the USAPI was fairly similar to US 
national NBCCEDP Pap test results. The overall percentages of abnormal Pap test results in 
first and subsequent screening rounds were 2.4% and 1.8% for the USAPI grantees from 
2007 to 2015, and these were 3.3% and 2.2%, respectively, for the national NBCCEDP data 
from 2003 to 2014 (NBCCEDP program staff in Atlanta, personal communication, 
December 15, 2016). In women aged 40 years or younger, the percentage of abnormal Pap 
test results in the US nationalNBC-CEDP data is observed to decrease by about half in first 
versus subsequent rounds [13]; however, this reduction in the percentage of abnormal Pap 
test results was not observed in subsequent rounds in the USAPI program data, possibly due 
to challenges in follow-up or treatment of precancerous lesions in women in the USAPI.
The majority of biopsy-confirmed cases detected in the USAPI were CIN2 or worse (57%); 
this was higher than the proportion of CIN2 or worse lesions observed in the US national 
NBCCEDP data (38% for the 2010–2015 period) [16]. The majority of ICC (90%) and high-
grade CIN (55%) cases in the USAPI, occurred in women aged 40 years or older; however, 
the majority of low-grade CIN cases and abnormal Pap test results were observed in younger 
women. These findings are consistent with those from national NBCCEDP data and with the 
natural history of cervical cancer disease (NBCCEDP program staff in Atlanta, personal 
communication, December 15, 2016) [17]. The higher percentage of abnormal Pap test 
results in women aged 40 years and younger may also be due to referral of women with 
suspected cervical abnormalities from reproductive health clinics or programs into the 
NBCCEDP for cervical cancer screening and diagnosis.
We found that roughly one third (32%) of Pap screens with results warranting follow-up or 
diagnostic testing (results of LSIL or worse, or ASC-US with HPV-Positive results) had no 
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data recorded on diagnostic tests or follow-up done. NBCCEDP program staff in the USAPI 
identified some of the reasons for the lack of data on follow-up or diagnostic tests to include: 
travel of women off-island for a second opinion, failure to contact women in outer islands, 
women not showing up for scheduled follow-up visits, and refusal of women to undergo 
diagnostic tests for various reasons such as fear of outcomes or the absence of female 
providers to conduct diagnostic tests (NBCCEDP program staff in the USAPI, personal 
communication, December 6, 2016). These and more challenges to following-up women 
screened for cervical cancer in the USAPI such as the lack of transportation for women to 
get to the clinics for follow-up, the fact that most women in the USAPI do not have phones, 
and the resistance of male partners to have their spouses examined for cervical cancer, have 
been discussed in the literature [11,18]. Since follow-up data was examined for each Pap 
screen conducted, it is possible that some tests may lack follow-up information because 
repeat Pap tests were conducted. However, the proportion of repeat Pap tests conducted in 
the US national NBCCEDP data has been previously found to be low (8.6% for ASC-US 
results) and would only explain a small fraction of the of Pap tests that lack information on 
follow-up or diagnostic testing in this analysis [19]. We also found that a small number of 
Pap screens with normal results reported having diagnostic tests done, including colposcopy 
with directed biopsy. These Pap screens need to be further investigated; they may be 
surveillance Pap tests for women with previously abnormal results that may have not been 
captured, or they may reflect the need for continued education of healthcare providers on 
evidence based practices and algorithms for cervical cancer screening and treatment.
The interpretation of findings on HPV testing and outcomes in this analysis may be limited 
by incomplete data for 2007–2008, since NBCCEDP programs were not required to 
comprehensively report on HPV tests and outcomes until 2009. Interpretations of outcomes 
by first program screening versus subsequent program screening are limited by the lack of 
information on women’s cervical cancer screening history and outcomes prior to entering 
the NBCCEDP.
5. Conclusion
In this analysis of cervical cancer screening in the USAPIs, we found that the distribution of 
Pap test results from the NBCCEDP’s USAPI grantees was fairly similar to that observed in 
US national NBCCEDP data; however, women in USAPI appeared to have a greater 
proportion of biopsy-confirmed high grade lesions (CIN2 or worse), compared to national 
NBCCEDP data. We also found that the screening programs in the USAPI had no 
information on follow-up or diagnostic services for roughly one-third of cases; this is likely 
due to geographical, technical and cultural challenges in providing diagnostic services and 
recording follow-up data, most of which are unique to the USAPI region. The NBCCEDP 
continues to work with the USAPI screening programs to thoroughly review and verify the 
data on women lost to follow-up after each program data submission, and examine ways to 
track these women for diagnostic services, and treatment initiation, if needed. The screening 
programs in the USAPI should further examine specific barriers to follow-up of women with 
abnormal Pap results and possible solutions to address them. The CDC’s Division of Cancer 
Prevention and Control, along with partners including the Title X Family Planning program, 
the Maternal Child Health program and the HRSA Community Health Center Program, 
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continue to examine resource-appropriate strategies to increase cervical cancer screening 
and treatment of precancerous lesions in the USAPI, taking into account the unique 
geographical, technical and socioeconomic challenges faced in this region [11].
The findings and conclusion of this analysis do not necessarily represent the official position 
of the U.S. Centers for Disease Control and Prevention.
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Fig. 1. 
Map of the six US- Affiliated Pacific Islandsa.
aThe National Breast and Cervical Cancer Early Detection Program (NBCCEDP) was 
implemented in four US–Affiliated Pacific Islands between 2007 and 2015: American 
Samoa, Guam, the Commonwealth of the Northern Mariana Islands (CNMI) and the 
Republic of Palau.
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Fig. 2. 
(a) Total number of Papanicolaou (Pap) tests provided by the National Breast and Cervical 
Cancer Early Detection Program by year in four US-Affiliated Pacific Islands, 2007–2015a.
aThe National Breast and Cervical Cancer Early Detection Program (NBCCEDP) was 
implemented in four US-Affiliated Pacific Islands between 2007 and 2015: American 
Samoa, Guam, the Commonwealth of the Northern Mariana Islands (CNMI) and the 
Republic of Palau.
bTotals exclude Pap tests with unsatisfactory/other results.
cTotals exclude women with unsatisfactory/other Pap test results
(b) Total number of human papillomavirus(HPV) tests provided by the National Breast and 
Cervical Cancer Early Detection Program by year in four US-Affiliated Pacific Islands, 
2007–2015.
aThe National Breast and Cervical Cancer Early Detection Program (NBCCEDP) was 
implemented in four US-Affiliated Pacific Islands between 2007 and 2015: American 
Samoa, Guam, the Commonwealth of the Northern Mariana Islands (CNMI) and the 
Republic of Palau. Only two of the four USAPIs performed HPV testing between 2007 and 
2015.
Abbreviations: Pap test, Papanicolaou Test.
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Table 1
Description of the four US-Affiliated Pacific Islands receiving support for cervical cancer screening through 
the National Breast and Cervical Cancer Early Detection Program.
American Samoa Commonwealth of 
the Northern 
Mariana Islands 
(CNMI)
Guam The Republic of Palau
Political status with U.S. Territory Commonwealth Territory Freely Associated
Population (est. 2012)a,b 55, 519 53, 883 159, 358 20,518
Number of islands 7 (5 inhabited) 14 (most residents 
live on 3 islands)
1 340 (9 inhabited)
Number of eligible women age 20–64b 13,776 16, 398 44,123 5215
Cervical Cancer Screening Resources
NBCCEDP (CDC) Yes Yes Yes Yes
Title X – Family Planning (HHS) Yes Yes Yes Yes
Community health centers (HRSA) 3 sites 1 site 2 sites 4 sites
MCH Block Grant (HRSA) Yes Yes Yes Yes
Local cervical pathology lab services 
availablec,d
No No No No
Number of cytopathologists/pathologistsc 1/1 0/0 0/1 0/0
Referral practices for women with positive 
screening test results who require treatmentc
Referral to LBJ 
Tropical Medical 
Center; Hawaii
Referral to 
community health 
center; Philippines, 
or Hawaii
Referral to 
Medical Social 
Services; 
Philippines, or 
Hawaii
Philippines, or Hawaii
Abbreviations: CDC, Centers for Disease Control and Prevention; NBCCEDP, National Breast and Cervical Cancer Early Detection Program, 
HHS, US Department of Health and Human Services; HRSA, Health Resources and Services Administration; MCH, Maternal and Child Health, 
LBJ Tropical Medical Center, Lyndon B. Johnson Tropical Medical Center in American Samoa.
aUS Census Bureau; 2010 Census Island Areas [updated August 2013]. Available from: http://www.census.gov/2010census/news/press-kits/island-
areas/island-areas.html. Accessed 12/6/2016.
bOffice on Women’s Health. Quick Health Data Online. Washington, DC: US Department of Health and Human Services, 2012. Health Status of 
Women in Region IX. Available at: http://52.207.219.3/qhdo/Reg09%20Report.pdf. Accessed 12/06/2016.
c
Ref. [14].
d
Personal Communication 12/6/2016 with NBCCEDP Program Staff from the US-Affiliated Pacific Islands.
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